HSBC lowered the firm’s price target on Teva (TEVA) to $20 from $24 and keeps a Buy rating on the shares. The firm says the confluence of first-time U.S. tariffs risks combined with a large patent cliff and Part D/Inflation Reduction Act headwinds might create some pressure on biopharma earnings. HSBC’s analysis suggests innovative pharma could face earnings headwinds of roughly 6%-14% if a 25% U.S. tariff were applied. A closer scrutiny of accounts and supply chains reveals potential risks to earnings might stem from other mechanisms such as tax rates, depending on how tariffs are structured, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva Pharmaceutical’s Strategic Focus on EBITDA Growth and Cost Efficiencies Drives Buy Rating
- Teva call volume above normal and directionally bullish
- Bausch says court grants summary judgment in favor of FDA, Salix, and Teva
- Teva put volume heavy and directionally bearish
- Teva, Samsung Bioepis announce EPYSQLI availability in the U.S.